Montauk Renewables (MNTK) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Q2 2024 revenue was $43.3M, down 18.6% year-over-year, mainly due to a strategic delay in RIN sales amid price volatility and weather-related disruptions, though realized RIN prices rose 44.4% to $3.12 per RIN.
Net loss for Q2 2024 was $0.7M, compared to net income of $1.0M in Q2 2023; six-month net income was $1.1M versus a $2.8M loss in the prior year period.
Strategic decision to hold 4.7M RINs in Q2, all sold in Q3 at higher prices.
Major development projects progressed, including Pico digestion expansion, North Carolina reactor commissioning, and ongoing investments in Second Apex, Blue Granite, and Bowerman RNG facilities.
Six-month revenues were $82.1M, up from $72.4M in the prior year.
Financial highlights
Q2 2024 operating income was $0.9M, down 93.6% year-over-year; net loss was $0.7M.
Adjusted EBITDA for Q2 2024 was $7.0M (down from $19.2M); six-month Adjusted EBITDA was $16.4M (up from $10.8M).
Cash and cash equivalents at June 30, 2024: $42.3M; total assets: $362M; total liabilities: $107M.
Cash from operations increased 138.4% to $14.5M; capital expenditures for H1 2024 were $40.8M.
Operating and maintenance expenses for RNG facilities rose 18.9%.
Outlook and guidance
Full-year 2024 RNG production guidance reaffirmed at 5.8–6.1M MMBtu and revenue at $195–$215M.
Renewable electricity production guidance held at 190,000–200,000 MWh and revenue at $18–$19M.
Major capital projects (Second Apex, Blue Granite, Bowerman, Montauk Ag Renewables) are progressing, with significant commissioning and revenue generation expected in 2025 and beyond.
Guidance incorporates weather-related impacts and anticipates further well field investments to offset disruptions.
Management expects sufficient liquidity from operations and credit facility to fund obligations and growth initiatives over the next 12–24 months.
Latest events from Montauk Renewables
- Net income plunged on flat revenue as RIN prices fell, but 2026 guidance expects growth.MNTK
Q4 202512 Mar 2026 - Q3 2024 revenue up 18.4% and net income up 31.8%, but project delays persist.MNTK
Q3 202414 Jan 2026 - Net income fell 34.9% to $9.7M on flat revenue, with 2025 RNG revenue guidance at $150–$170M.MNTK
Q4 202426 Dec 2025 - Director elections, auditor ratification, and strategic growth initiatives highlight the 2025 meeting.MNTK
Proxy Filing1 Dec 2025 - Shareholders to elect two directors and ratify Grant Thornton LLP as auditor at the annual meeting.MNTK
Proxy Filing1 Dec 2025 - Revenue up 9.8%, but net loss and regulatory delays challenge outlook; major capex planned.MNTK
Q1 202526 Nov 2025 - Q2 2025 revenue rose 4.1% but net loss widened on lower RIN prices and higher costs.MNTK
Q2 202523 Nov 2025 - Q3 2025 revenue and net income fell sharply on lower RIN sales and prices; capex remains high.MNTK
Q3 202513 Nov 2025